By Michael Susin

AstraZeneca PLC said on Thursday that its metastatic breast cancer treatment Enhertu has been approved for use in the U.S.

The Anglo-Swedish pharma giant said Enhertu will be used in patients with breast cancer that were treated with a prior treatment and have developed disease recurrence during or within six months of completing therapy.

The company said clinical studies showed that the treatment has reduced the risk of disease progression or death by 72% when compared with other treatment.

Enhertu its a jointly treatment developed and commercialized by AstraZenecaa and Daiichi Sankyo Co.

Astrazeneca said regulatory applications are currently under review in Europe, Japan and several other countries.

Write to Michael Susin at michael.susin@wsj.com

(END) Dow Jones Newswires

May 05, 2022 02:48 ET (06:48 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Astrazeneca.